Publication:

Cancer Nanomedicine: From Targeted Delivery to Combination Therapy

Loading...
Thumbnail Image

Open/View Files

Date

2015

Journal Title

Journal ISSN

Volume Title

Publisher

The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Xu, Xiaoyang, William Ho, Xueqing Zhang, Nicolas Bertrand, and Omid Farokhzad. 2015. “Cancer Nanomedicine: From Targeted Delivery to Combination Therapy.” Trends in molecular medicine 21 (4): 223-232. doi:10.1016/j.molmed.2015.01.001. http://dx.doi.org/10.1016/j.molmed.2015.01.001.

Abstract

The advent of nanomedicine marks an unparalleled opportunity to advance the treatment of a variety of diseases, including cancer. The unique properties of nanoparticles, such as large surface-to volume ratio, small size, the ability to encapsulate a variety of drugs, and tunable surface chemistry, gives them many advantages over their bulk counterparts. This includes multivalent surface modification with targeting ligands, efficient navigation of the complex in vivo environment, increased intracellular trafficking, and sustained release of drug payload. These advantages make nanoparticles a mode of treatment potentially superior to conventional cancer therapies. This article highlights the most recent developments in cancer treatment using nanoparticles as drug-delivery vehicles, including promising opportunities in targeted and combination therapy.

Description

Research Data

Keywords

Nanomedicine, Targeted Delivery, Combination Therapy, Cancer

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories